221 SYNERGY-1: A Phase 1, first-in-human, randomized, double-blind, placebo-controlled safety, tolerability, immunogenicity, PK and PD study of KP104 in escalating single and multiple doses
Wabinitz, Paul, Ma, Jay, Tsui, Ping, Fu, Helen, He, Chaomei, Wu, Jingtao, Yu Christina Weng, Qing, Rankin, Jon, Song, Wenru, Farinola, Nicholas, Lee, Richard
Published in Immunobiology (1979) (01.09.2023)
Published in Immunobiology (1979) (01.09.2023)
Get full text
Journal Article